Pharma major Novartis is becoming more optimistic about some of its biggest growth drugs, even as investors question the company's ability to sustain growth beyond 2031 and offset the financial impact of older drugs' patent expiries. The Swiss drugmaker now expects multiple sclerosis drug Kesimpta, leukaemia treatment Scemblix, and cholesterol medicine Leqvio to generate $18 billion in peak sales, up from a previous forecast of $14 billion combined. CEO Vas Narasimhan said the upgrades were driven primarily by strong commercial performance, pointing to growing market share for Kesimpta and Scemblix and robust demand for Leqvio in the U.S. and Asia.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
